Grail (GRAL) said Wednesday it has seen better cancer detection results from an analysis of the first 25,578 participants in its Pathfinder 2 study compared with the previous Pathfinder study.
The Pathfinder 2 study was launched in 2021 to assess the safety and performance of the Galleri cancer detection test when added to standard of care in 35,878 adults with more than 50 years of age and with no clinical suspicion of cancer, Grail said.
In Pathfinder 2, adding Galleri to standard of care tests showed "substantially greater additional cancer detection" than in the prior study, the company said.
The results from the latest study also indicated a "substantially higher" positive predictive value than that seen in the previous study, Grail said.
The company also said "no serious safety concerns" were seen in the Pathfinder 2 study.
Grail shares were up more than 4% in recent early trading.
Price: 43.97, Change: +1.92, Percent Change: +4.57
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.